EGFR and cancer: Some combinations represent a dual blockade in pathways related to different hallmarks of cancer (Figure 1), such as the combination of bevacizumab and erlotinib for advanced liver cancer, which targets both tumor neovascularization and proliferative signaling (EGFR and vascular endothelial growth factor dual blockade, Table 4).